顺铂联合紫杉醇或伊立替康治疗晚期宫颈癌的疗效分析

Analysis on Therapeutic Effect of Cisplatin Combined with Paclitaxel or Irinotecan on Advanced Cervical Cancer

目的:比较伊立替康联合顺铂与紫杉醇联合顺铂治疗晚期宫颈癌的临床疗效。方法:选择2014年6月—2016年6月我院收治的晚期宫颈癌患者60例,按随机数字表法分为紫杉醇联合顺铂组(TP)和伊立替康联合顺铂组(IP),各30例。比较两组客观缓解率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)、总生存期(OS)和不良反应。结果 :两组ORR、DCR、OS比较,差异无统计学意义(P> 0.05);IP组PFS短于TP组,差异有统计学意义(P=0.015);TP组肝肾功能异常和脱发发生率高于IP组,差异有统计学意义(P <0.05)。结论:IP方案治疗晚期宫颈癌的近期临床疗效与TP方案相当,但IP组安全性更好,且可明显改善患者的无进展生存时间。

Objective:To compare the clinical efficacy of irinotecan combined with cisplatin and paclitaxel in combination with cisplatin in the treatment of advanced cervical cancer.Methods:66 patients with advanced cervical cancer admitted to our hospital from June 2014 to June 2016 were selected and randomly divided into a paclitaxel plus cisplatin(TP)group and irinotecan plus cisplatin(IP)group,30 cases each.The objective response rates(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and adverse reactions were compared between the two groups.Results:There were no statistically significant differences in ORR,DCR and OS between the two groups(P>0.05).The PFS in the IP group was shorter than that in the TP group,and the difference was statistically significant(P=0.015).The incidences of liver and kidney dysfunction and alopecia in the TP group were higher than those in the IP group,and the differences were statistically significant(P<0.05).Conclusion:The short-term clinical efficacy of the IP regimen is comparable to that of the TP regimen in the treatment of advanced cervical cancer,but the safety in the IP group is better and the progression-free survival of the patients can be significantly improved.